The Biology and Pathobiology of Glutamatergic, Cholinergic, and Dopaminergic Signaling in the Aging Brain
Open accessThe DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Abstract
The elderly population is growing worldwide, with important health and socioeconomic implications. Clinical and experimental studies on aging have uncovered numerous changes in the brain, such as decreased neurogenesis, increased synaptic defects, greater metabolic stress, and enhanced inflammation. These changes are associated with cognitive decline and neurobehavioral deficits. Although aging is not a disease, it is a significant risk factor for functional worsening, affective impairment, disease exaggeration, dementia, and general disease susceptibility. Conversely, life events related to mental stress and trauma can also lead to accelerated age-associated disorders and dementia. Here, we review human studies and studies on mice and rats, such as those modeling human neurodegenerative diseases, that have helped elucidate (1) the dynamics and mechanisms underlying the biological and pathological aging of the main projecting systems in the brain (glutamatergic, cholinergic, and dopaminergic) and (2) the effect of defective glutamatergic, cholinergic, and dopaminergic projection on disabilities associated with aging and neurodegenerative disorders, such as Alzheimer’s and Parkinson’s diseases. Detailed knowledge of the mechanisms of age-related diseases can be an important element in the development of effective ways of treatment. In this context, we briefly analyze which adverse changes associated with neurodegenerative diseases in the cholinergic, glutaminergic and dopaminergic systems could be targeted by therapeutic strategies developed as a result of our better understanding of these damaging mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
Predictive reward signal of dopamine neurons
Schultz, W. (1998) · Journal of Neurophysiology · doi:10.1152/jn.1998.80.1.1 · Cited by 4,564
Neurotrophins: Roles in Neuronal Development and Function
Huang, E. J., & Reichardt, L. F. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.677 · Cited by 4,394
Dopamine receptors: from structure to function
MISSALE, C., NASH, S. R., ROBINSON, S. W., JABER, M., & CARON, M. G. (1998) · Physiological Reviews · doi:10.1152/physrev.1998.78.1.189 · Cited by 3,633
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565 · cited 2×
“Reduction in ChAT activity (Davies, 1976; Perry et al., 1977; Rossor et al., 1982; Wilcock et al., 1982), cholinergic receptor number (Nordberg and Winblad, 1986), AChE activity (Davies, 1976; Geula and Mesulam, 1995), and decrease in high affinity choline uptake have been observed in AD (Rylett et…”
BackgroundNeuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
Ageing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310
Mesulam, M. ‐., Mufson, E. J., Levey, A. I., & Wainer, B. H. (1983) · Journal of Comparative Neurology · doi:10.1002/cne.902140206 · Cited by 1,962
Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821
Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease
Gómez-Isla, T., Price, J. L., McKeel Jr., D. W., Morris, J. C., Growdon, J. H., & Hyman, B. T. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-14-04491.1996 · Cited by 1,796
Dopamine neuron systems in the brain: An update
Björklund, A., & Dunnett, S. B. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.006 · Cited by 1,777
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744 · cited 1×
“…approved since the approval of memantine (an NMDAR antagonist) in 2003 following the approval in 2001 of galantamine, the last of four acetylcholine esterase inhibitors (AChEIs) (the others being tacrine, donepezil, rivastigmine) recommended in the treatment of dementia (Cummings et al., 2014).”
BackgroundAlzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981) · Annals of Neurology · doi:10.1002/ana.410100203 · Cited by 1,736
Mammalian nicotinic acetylcholine receptors: from structure to function
Albuquerque, E. X., Pereira, E. F. R., Alkondon, M., & Rogers, S. W. (2009) · Physiological Reviews · doi:10.1152/physrev.00015.2008 · Cited by 1,724
Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways
Hardingham, G. E., Fukunaga, Y., & Bading, H. (2002) · Nature Neuroscience · doi:10.1038/nn835 · Cited by 1,686
Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders
Hardingham, G. E., & Bading, H. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2911 · Cited by 1,644
Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592
Acetylcholine as a Neuromodulator: Cholinergic Signaling Shapes Nervous System Function and Behavior
Picciotto, M. R., Higley, M. J., & Mineur, Y. S. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.036 · Cited by 1,404
Nerve Growth Factor Signaling, Neuroprotection, and Neural Repair
Sofroniew, M. V., Howe, C. L., & Mobley, W. C. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1217 · Cited by 1,284
Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease
West, M. J., Coleman, P. D., Flood, D. G., & Troncoso, J. C. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92338-8 · Cited by 1,267
Normal aging induces A1-like astrocyte reactivity
Clarke, L. E., Liddelow, S. A., Chakraborty, C., Münch, A. E., Heiman, M., & Barres, B. A. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1800165115 · Cited by 1,237
Terry, A. V., & Buccafusco, J. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041616 · Cited by 1,159
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
Hoover, B. R., Reed, M. N., Su, J., Penrod, R. D., Kotilinek, L. A., Grant, M. K., Pitstick, R., Carlson, G. A., Lanier, L. M., Yuan, L.-L., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.11.030 · Cited by 1,118
NMDA receptor-dependent long-term potentiation and long-term depression (LTP/LTD).
Luscher, C., & Malenka, R. C. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a005710 · Cited by 1,110
Role of Glutamate and NMDA Receptors in Alzheimer’s Disease
Wang, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160763 · Cited by 1,009
Addiction: Beyond dopamine reward circuitry
Volkow, N. D., Wang, G.-J., Fowler, J. S., Tomasi, D., & Telang, F. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010654108 · Cited by 959
Long-term depression in the CNS
Collingridge, G. L., Peineau, S., Howland, J. G., & Wang, Y. T. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2867 · Cited by 926
De Felice, F. G., Velasco, P. T., Lambert, M. P., Viola, K., Fernandez, S. J., Ferreira, S. T., & Klein, W. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607483200 · Cited by 882
GDNF, NGF and BDNF as Therapeutic Options for Neurodegeneration
Allen, S. J., Watson, J. J., Shoemark, D. K., Barua, N. U., & Patel, N. K. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.004 · Cited by 820
Fjell, A. M., McEvoy, L., Holland, D., Dale, A. M., & Walhovd, K. B. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.02.004 · Cited by 799
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782
Neuron numbers and dendritic extent in normal aging and Alzheimer’s disease
Coleman, P. D., & Flood, D. G. (1987) · Neurobiology of Aging · doi:10.1016/0197-4580(87)90127-8 · Cited by 772
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease
Zucca, F. A., Segura-Aguilar, J., Ferrari, E., Muñoz, P., Paris, I., Sulzer, D., Sarna, T., Casella, L., & Zecca, L. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.09.012 · Cited by 659
Structural and Molecular Remodeling of Dendritic Spine Substructures during Long-Term Potentiation
Bosch, M., Castro, J., Saneyoshi, T., Matsuno, H., Sur, M., & Hayashi, Y. (2014) · Neuron · doi:10.1016/j.neuron.2014.03.021 · Cited by 637
Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss
Talantova, M., Sanz-Blasco, S., Zhang, X., Xia, P., Akhtar, M. W., Okamoto, S.-I., Dziewczapolski, G., Nakamura, T., Cao, G., Pratt, A. E., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1306832110 · Cited by 600
Neuron Number in the Entorhinal Cortex and CA1 in Preclinical Alzheimer Disease
Price, J. L., Ko, A. I., Wade, M. J., Tsou, S. K., McKeel, D. W., & Morris, J. C. (2001) · Archives of Neurology · doi:10.1001/archneur.58.9.1395 · Cited by 596
Wilcock, G. K., Esiri, M. M., Bowen, D. M., & Smith, C. C. T. (1982) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(82)90045-4 · Cited by 553
Dopamine and Cognitive Control in Prefrontal Cortex
Ott, T., & Nieder, A. (2019) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2018.12.006 · Cited by 530 · cited 1×
“The mesocorticolimbic ascending dopaminergic pathways to the prefrontal cortex are implicated in cognitive control of working memory and reward-based learning (Cools et al., 2019; Ott and Nieder, 2019; Douma and de Kloet, 2020).”
BackgroundDopaminergic terminals in the nucleus accumbens but not the dorsal striatum corelease glutamate
Stuber, G. D., Hnasko, T. S., Britt, J. P., Edwards, R. H., & Bonci, A. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.1754-10.2010 · Cited by 529
Synaptic degeneration in Alzheimer's disease
Arendt, T. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0536-x · Cited by 517 · cited 1×
“The reduction in the number of synapses containing glutamatergic receptors and dendritic branching dystrophy occurs in the early stage of AD and may affect the severity of the disease (Arendt, 2009; Pozueta et al., 2013; Benarroch, 2018).”
BackgroundNobili, A., Latagliata, E. C., Viscomi, M. T., Cavallucci, V., Cutuli, D., Giacovazzo, G., Krashia, P., Rizzo, F. R., Marino, R., Federici, M., et al. (2017) · Nature Communications · doi:10.1038/ncomms14727 · Cited by 514
BDNF as a Promising Therapeutic Agent in Parkinson’s Disease
Palasz, E., Wysocka, A., Gasiorowska, A., Chalimoniuk, M., Niewiadomski, W., & Niewiadomska, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031170 · Cited by 504
Self-citationDeficient glutamate tranport is associated with neurodegeneration in Alzheimer's disease
Masliah, E., Hansen, L., Alford, M., Deteresa, R., & Mallory, M. (1996) · Annals of Neurology · doi:10.1002/ana.410400512 · Cited by 476
Network perspectives on the mechanisms of deep brain stimulation
McIntyre, C. C., & Hahn, P. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.09.022 · Cited by 439
Striatal dopamine neurotransmission: Regulation of release and uptake
Sulzer, D., Cragg, S. J., & Rice, M. E. (2016) · Basal Ganglia · doi:10.1016/j.baga.2016.02.001 · Cited by 382
Neuron-glia signaling in synapse elimination
Wilton, D. K., Dissing-Olesen, L., & Stevens, B. (2019) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070918-050306 · Cited by 332
Jacob, C. P., Koutsilieri, E., Bartl, J., Neuen-Jacob, E., Arzberger, T., Zander, N., Ravid, R., Roggendorf, W., Riederer, P., & Grünblatt, E. (2007) · Journal of Alzheimer's Disease · doi:10.3233/jad-2007-11113 · Cited by 317
McShane, R., Westby, M. J., Roberts, E., Minakaran, N., Schneider, L., Farrimond, L. E., Maayan, N., Ware, J., & Debarros, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub6 · Cited by 310
Neuronal nicotinic acetylcholine receptor structure and function and response to nicotine
Dani, J. A. (2015) · International Review of Neurobiology · doi:10.1016/bs.irn.2015.07.001 · Cited by 309 · cited 1×
“Nicotinic receptors consist of five subunits and combine into heteromeric and homomeric pentamers (Dani, 2015).”
BackgroundDiversity of native nicotinic receptor subtypes in mammalian brain
Zoli, M., Pistillo, F., & Gotti, C. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.11.003 · Cited by 277
Complement System in Neural Synapse Elimination in Development and Disease
Presumey, J., Bialas, A. R., & Carroll, M. C. (2017) · Advances in Immunology · doi:10.1016/bs.ai.2017.06.004 · Cited by 276
Porsteinsson, A., Grossberg, G., Mintzer, J., & Olin, J. (2008) · Current Alzheimer Research · doi:10.2174/156720508783884576 · Cited by 272
Nucleus accumbens medium spiny neurons subtypes signal both reward and aversion
Soares-Cunha, C., de Vasconcelos, N. A. P., Coimbra, B., Domingues, A. V., Silva, J. M., Loureiro-Campos, E., Gaspar, R., Sotiropoulos, I., Sousa, N., & Rodrigues, A. J. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0484-3 · Cited by 256
Di Domenico, F., Tramutola, A., & Butterfield, D. A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.10.490 · Cited by 253
Kaiser, L. G., Schuff, N., Cashdollar, N., & Weiner, M. W. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.07.001 · Cited by 251
Burns, R. S., LeWitt, P. A., Ebert, M. H., Pakkenberg, H., & Kopin, I. J. (1985) · New England Journal of Medicine · doi:10.1056/nejm198505303122203 · Cited by 244
Emerging Role for Nucleus Accumbens Medium Spiny Neuron Subtypes in Depression
Francis, T. C., & Lobo, M. K. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.09.007 · Cited by 230
Age-related changes in midbrain dopaminergic regulation of the human reward system
Dreher, J.-C., Meyer-Lindenberg, A., Kohn, P., & Berman, K. F. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802127105 · Cited by 230
Glutamate transporter variants reduce glutamate uptake in Alzheimer's disease
Scott, H. A., Gebhardt, F. M., Mitrovic, A. D., Vandenberg, R. J., & Dodd, P. R. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.008 · Cited by 202
Arnold, H. M., Burk, J. A., Hodgson, E. M., Sarter, M., & Bruno, J. P. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00292-0 · Cited by 195
Cholinergic stimulation enhances long-term potentiation in the CA1 region of rat hippocampus
Blitzer, R. D., Gil, O., & Landau, E. M. (1990) · Neuroscience Letters · doi:10.1016/0304-3940(90)90835-w · Cited by 192
Amyloid-β 1–42 Slows Clearance of Synaptically Released Glutamate by Mislocalizing Astrocytic GLT-1
Scimemi, A., Meabon, J. S., Woltjer, R. L., Sullivan, J. M., Diamond, J. S., & Cook, D. G. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.5274-12.2013 · Cited by 185
Dou, K.-X., Tan, M.-S., Tan, C.-C., Cao, X.-P., Hou, X.-H., Guo, Q.-H., Tan, L., Mok, V., & Yu, J.-T. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0457-9 · Cited by 171
Guo, J., Wang, Z., Liu, R., Huang, Y., Zhang, N., & Zhang, R. (2020) · Brain and Behavior · doi:10.1002/brb3.1831 · Cited by 165
The Cortico-Basal Ganglia-Cerebellar Network: Past, Present and Future Perspectives
Milardi, D., Quartarone, A., Bramanti, A., Anastasi, G., Bertino, S., Basile, G. A., Buonasera, P., Pilone, G., Celeste, G., Rizzo, G., et al. (2019) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2019.00061 · Cited by 162
Postsynaptic signaling during plasticity of dendritic spines
Murakoshi, H., & Yasuda, R. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.12.002 · Cited by 158
Banerjee, R., Ghosh, A. K., Ghosh, B., Bhattacharyya, S., & Mondal, A. C. (2013) · Clinical Medicine Insights: Pathology · doi:10.4137/cpath.s12530 · Cited by 135
Atri, A., Molinuevo, J. L., Lemming, O., Wirth, Y., Pulte, I., & Wilkinson, D. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt160 · Cited by 126
Deardorff, W. J., & Grossberg, G. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s86463 · Cited by 125
Age and Alzheimer’s disease gene expression profiles reversed by the glutamate modulator riluzole
Pereira, A. C., Gray, J. D., Kogan, J. F., Davidson, R. L., Rubin, T. G., Okamoto, M., Morrison, J. H., & McEwen, B. S. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.33 · Cited by 116
Trudler, D., Sanz-Blasco, S., Eisele, Y. S., Ghatak, S., Bodhinathan, K., Akhtar, M. W., Lynch, W. P., Piña-Crespo, J. C., Talantova, M., Kelly, J. W., et al. (2021) · The Journal of Neuroscience · doi:10.1523/jneurosci.1871-20.2020 · Cited by 104
Expression of Nerve Growth Factor and trkA After Transient Focal Cerebral Ischemia in Rats
Lee, T.-H., Kato, H., Chen, S.-T., Kogure, K., & Itoyama, Y. (1998) · Stroke · doi:10.1161/01.str.29.8.1687 · Cited by 103
Cognitive impact of neuronal pathology in the entorhinal cortex and CA1 field in Alzheimer's disease
GUNTEN, A., KOVARI, E., BUSSIERE, T., RIVARA, C., GOLD, G., BOURAS, C., HOF, P., & GIANNAKOPOULOS, P. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.02.008 · Cited by 101 · cited 1×
“…with AD, there is evidence of a loss of glutamatergic neurons, especially in the neocortex (layers III and IV) and the CA1 region of the hippocampus (West et al., 1994; Gómez-Isla et al., 1996; Simić et al., 1997; de Toledo-Morrell et al., 2000; Price et al., 2001; von Gunten et al., 2006).”
BackgroundPalasz, E., Niewiadomski, W., Gasiorowska, A., Wysocka, A., Stepniewska, A., & Niewiadomska, G. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01143 · Cited by 95
Self-citationChen, X., Lin, R., Chang, L., Xu, S., Wei, X., Zhang, J., Wang, C., Anwyl, R., & Wang, Q. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.08.054 · Cited by 93
Age-related decline in nicotinic receptor availability with [123I]5-IA-85380 SPECT
Mitsis, E. M., Cosgrove, K. P., Staley, J. K., Bois, F., Frohlich, E. B., Tamagnan, G. D., Estok, K. M., Seibyl, J. P., & van Dyck, C. H. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.12.008 · Cited by 65
Schmitt, F. A., van Dyck, C. H., Wichems, C. H., & Olin, J. T. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213860.35355.d4 · Cited by 62
Bananej, M., Karimi-Sori, A., Zarrindast, M. R., & Ahmadi, S. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111405556 · Cited by 52
Psychological Predictors of Anxiety and Depression in Parkinson's Disease: A Systematic Review
Garlovsky, J. K., Overton, P. G., & Simpson, J. (2016) · Journal of Clinical Psychology · doi:10.1002/jclp.22308 · Cited by 49
Shimada, H., Hirano, S., Sinotoh, H., Ota, T., Tanaka, N., Sato, K., Yamada, M., Fukushi, K., Irie, T., Zhang, M. R., et al. (2015) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4338 · Cited by 40
Palasz, E., Niewiadomski, W., Gasiorowska, A., Mietelska-Porowska, A., & Niewiadomska, G. (2019) · Neural Plasticity · doi:10.1155/2019/8215017 · Cited by 39
Self-citationDifferential effects of nicotine exposure on the hippocampus across lifespan
Zeid, D., Kutlu, M. G., & Gould, T. J. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170714092436 · Cited by 36
Cited by
Role of Cholinergic Signaling in Alzheimer’s Disease
Chen, Z.-R., Huang, J.-B., Yang, S.-L., & Hong, F.-F. (2022) · Molecules · doi:10.3390/molecules27061816 · Cited by 922
“In addition, life events related to mental stress and trauma can also lead to accelerated age-related diseases including AD [94].”
BackgroundAstrocytes in human central nervous system diseases: a frontier for new therapies
Verkhratsky, A., Butt, A., Li, B., Illes, P., Zorec, R., Semyanov, A., Tang, Y., & Sofroniew, M. V. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01628-9 · Cited by 428
Astrocytic microRNAs and transcription factors in Alzheimer’s disease and therapeutic interventions
Nassar, A., Kodi, T., Satarker, S., Chowdari Gurram, P., Upadhya, D., SM, F., Mudgal, J., & Nampoothiri, M. (2022) · Cells · doi:10.3390/cells11244111 · Cited by 38
The Role of Glutamine Homeostasis in Emotional and Cognitive Functions
Baek, J. H., Park, H., Kang, H., Kim, R., Kang, J. S., & Kim, H. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021302 · Cited by 35
“Most glutamatergic neurons are distributed in the frontal cortex [4] and consume more than 80% of the total brain energy budget [5].”
Background
Metadata
- Authors
- Gasiorowska, A., Wydrych, M., Drapich, P., Zadrozny, M., Steczkowska, M., Niewiadomski, W., & Niewiadomska, G.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2021-07-13
- Volume
- 13
- Pages
- 654931-654931
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W3178168279
- Cited by
- 184
- References
- 85
- FWCI
- 9.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.